top of page
an_banners (6).png

SuRE™ Promoters &
AIM™ Integration Sites

Bespoke qualified promoters for controlled gene expression in cell and gene therapy or protein and virus production.


Identification of optimal genomic integration sites for cell therapy and manufacturing cell lines.


Promoters For
Cell & Gene Therapy


SuRE™ screening to identify promoters for better control over the expression of your transgene.

Integration Site Mapping

an_icons (1).png

AIM™ service to identify favourable gene insertions and their expression levels for
cell engineering.

Cell Line Optimization

an_icons (3).png

SuRE™ endogenous promoters and integration site mapping for
CHO/HEK/other cell lines.

Off-The-Shelf Products

an_icon (1).png

Available SuRE™ promoters for licensing.

Promoter Optimization

an_icons (2).png

Exhaustive saturated mutagenizes creating new sequence of existing promoters or designs.

Learn More?


Reach out to us for our solutions in gene expression and cell engineering.


Introducing our experts

We have a team of highly skilled and enthusiastic scientists and technicians dedicated to our clients projects. In addition, they work on new developments around our SuRE™ platform to ensure its continuous improvement for pharmaceutical and agricultural applications. The team is led by founder Joris van Arensbergen and biotech entrepreneur Victor Schut.


Recent News & Events



Updates - December 2023  

Annogen signs deal in which SuRE™ libraries are used for in-vivo capsid screening

Annogen has signed a deal with an undisclosed gene therapy company for an AAV capsid screening project. For this project Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases for many capsids in parallel.



Updates - October 2023  

Annogen introduces HEK293-INDX1™ - a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production

Annogen is excited to share our latest breakthrough in cellular engineering. We've successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline expression and high inducibility with added stimulus.



Events - Annogen attending BIOEurope in Munich, November 6–8, 2023

Request a partnering meeting with P. Victor Schut, CBO ( and discuss the applications of:
- SuRE™ human promoters for cell and gene therapy
- CHO genome derived promoters for protein manufacturing, cell culture, and
- AIM™ integration site mapping for cell engineering (allogeneic, cell therapy and cell line generation).




Events - Annogen attending the virtual partnering at Alliance for Regenerative Medicine, October 17-18, 2023

Annogen plays a specific role in providing its SuRE™ human promoters (cell specific and/or inducible) and AIM™ integration mapping for cell engineering (e.g. allogeneic platforms).

Looking forward to connecting with senior executives and top stakeholders to tackle the most pressing issues in cell and gene therapies. Please contact ( to learn more about the Annogen qualified promoters and cell engineering capabilities.




PRESS RELEASE - April 2022 Annogen signs another collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA using SuRE™ screening technology.    

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.

Follow our activities on LinkedIn

  • LinkedIn - White Circle
an_banners (8).png
bottom of page